Clinical Trial

Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters

Recruiting
View on ClinicalTrials.gov →
Summary
The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV). Several centers, including ours, utilize pre-procedural computer tomography (CT) to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and introduce significant logistical challenges to the procedural workflow. The FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single tool. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA system, including the creation of voltage and activation maps. These features address the limitations of the first-generation FARAPULSE catheter and have the potential to improve procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may obviate the need for pre-procedural CT, thereby reducing costs and minimizing patient radiation exposure. Our study evaluates whether the FARAWAVE Nav catheter, used without pre-ablation CT, allows for a reduction in fluoroscopy time and overall patient radiation exposure compared to the conventional workflow with the FARAPULSE catheter. Furthermore, we will assess procedural time, costs, number of PFA applications, and AF recurrence-free survival
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-16.
Status change: Not Yet Recruiting → Recruiting 2026-03-17
Trial Details
NCT Number NCT07130773
Lead Sponsor Cardiocentro Ticino
Conditions Atrial Fibrillation (AF), Atrial Fibrillation Ablation, Pulsed Field Ablation
Enrollment 58 participants
Start Date 2025-11-10
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-19